Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Bristol Myers Squibb - Melanoma in 2020: Reflect, reset, and continue

Expert insights: Adapting treatment during the COVID-19 pandemic


14 Sep 2020


Bristol Myers Squibb - Melanoma in 2020: Reflect, reset, and continue


Pippa Corrie


J. Larkin1, P.A. Ascierto2, P. Corrie3

Author affiliations

  • 1 Medicine Department, The Royal Marsden Hospital - NHS Foundation Trust, SW3 6JJ - London/GB
  • 2 Melanoma, Cancer Immunotherapy & Developmental Therapeutics, Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, 80131 - Napoli/IT
  • 3 Department Of Oncology, Addenbrookes Hospital, Cambridge University Hospitals NHS Foundation Trust, CB2 0QQ - Cambridge/GB


Login to access the resources on OncologyPRO.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.